Last10K.com

Biomarin Pharmaceutical Inc (BMRN) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Biomarin Pharmaceutical Inc

CIK: 1048477 Ticker: BMRN

 

Exhibit 99.1

 

 

 

Contact:

 

 

Investors:

 

Media:

Traci McCarty

 

Debra Charlesworth

BioMarin Pharmaceutical Inc.

 

BioMarin Pharmaceutical Inc.

(415) 455-7558

 

(415) 455-7451

 

 

 

 

 

BioMarin Announces Third Quarter 2018 Results

 

- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion

- 124 Commercial Patients Receiving Treatment with Palynziq in First Full Quarter since U.S. Approval

- Vosoritide 42-Month Data; PKU Gene Therapy Preclinical Data and Research Deep Dive

at R&D Day on November 7 in New York City

 

 

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2018

 

 

2017

 

 

% Change

 

 

2018

 

 

2017

 

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$

391.7

 

 

$

334.1

 

 

 

17

%

 

$

1,138.0

 

 

$

955.3

 

 

 

19

%

Vimizim Net Product Revenues

 

 

123.3

 

 

 

90.3

 

 

 

37

%

 

 

368.0

 

 

 

299.3

 

 

 

23

%

Kuvan Net Product Revenues

 

 

113.3

 

 

 

105.8

 

 

 

7

%

 

 

321.4

 

 

 

300.1

 

 

 

7

%

Naglazyme Net Product Revenues

 

 

103.1

 

 

 

72.1

 

 

 

43

%

 

 

269.2

 

 

 

238.4

 

 

 

13

%

Aldurazyme Net Product Revenues

 

 

27.6

 

 

 

22.4

 

 

 

23

%

 

 

117.7

 

 

 

61.7

 

 

 

91

%

Brineura Net Product Revenues

 

 

9.9

 

 

 

3.1

 

 

 

219

%

 

 

27.7

 

 

 

3.4

 

 

 

715

%

Palynziq Net Product Revenues

 

 

4.1

 

 

 

 

 

n/a

 

 

 

4.1

 

 

 

 

 

n/a

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP Net Loss

 

$

(12.6

)

 

$

(12.5

)

 

 

 

 

 

$

(73.6

)

 

$

(65.7

)

 

 

 

 

GAAP Net Loss per Share - Basic and Diluted

 

$

(0.07

)

 

$

(0.07

)

 

 

 

 

 

$

(0.42

)

 

$

(0.38

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Income (1)

 

$

60.7

 

 

$

7.8

 

 

 

 

 

 

$

101.8

 

 

$

68.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

December 31,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and investments

 

$

1,648.3

 

 

$

1,781.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

Non-GAAP Income is defined by the Company as reported GAAP Net Income (Loss), excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items. Refer to Non-GAAP Information beginning on page 9 of this press release for a complete discussion of the Company’s Non-GAAP financial information and reconciliations to the comparable information reported under Generally Accepted Accounting Principles in the United States (US GAAP).

 

1

 


The following information was filed by Biomarin Pharmaceutical Inc (BMRN) on Thursday, October 25, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Biomarin Pharmaceutical Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biomarin Pharmaceutical Inc.

Continue

Assess how Biomarin Pharmaceutical Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Biomarin Pharmaceutical Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Cash Flow
Geography
Product
Income
Debt
Earnings
Other
Inside Biomarin Pharmaceutical Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Loss
Condensed Consolidated Statements Of Stockholders' Equity
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss (Tables)
Amounts Reclassified Out Of Aoci (Detail)
Anti-Dilutive Common Stock Excluded From Computation Of Diluted Net Loss Per Share (Detail)
Assumptions Used To Estimate Per Share Fair Value Of Stock Options Granted (Detail)
Basis Of Presentation
Benefit From Income Taxes
Benefit From Income Taxes - Additional Information (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Compensation Expense (Detail)
Debt
Debt (Tables)
Debt - Additional Information (Detail)
Derivative Instruments And Hedging Strategies
Derivative Instruments And Hedging Strategies (Tables)
Derivative Instruments And Hedging Strategies - Additional Information (Detail)
Disaggregates Of Total Net Product Revenues Based On Patient Location (Detail)
Disaggregates Of Total Net Product Revenues From External Customers By Product (Detail)
Disaggregates Of Total Revenues From External Customers And Collaborative Partners By Geographic Region (Detail)
Effect Of Derivative Instruments (Detail)
Fair Value Carrying Amount Of Derivative Instruments (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Of Financial Assets And Liabilities (Detail)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Additional Information (Detail)
Intangible Assets
Intangible Assets (Detail)
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Liabilities Measured At Fair Value Using Level 3 Inputs (Detail)
Nature Of Operations
Net Loss Per Common Share
Net Loss Per Common Share (Tables)
Net Loss Per Common Share - Additional Information (Detail)
Property Plant And Equipment - Additional Information (Detail)
Property, Plant And Equipment
Property, Plant And Equipment (Tables)
Recent Accounting Pronouncements
Recent Accounting Pronouncements (Tables)
Recent Accounting Pronouncements - Additional Information (Detail)
Recent Accounting Pronouncements - Summary Of Adjustments To Accounts On Condensed Consolidated Balance Sheet (Detail)
Recent Accounting Pronouncements - Summary Of Adjustments To Accounts On Condensed Consolidated Statement Of Cash Flows (Detail)
Recent Accounting Pronouncements - Summary Of Adjustments To Accounts On Condensed Consolidated Statements Of Comprehensive Loss (Detail)
Revenue, Credit Concentrations And Geographic Information
Revenue, Credit Concentrations And Geographic Information (Tables)
Revenue, Credit Concentrations And Geographic Information - Additional Information (Detail)
Schedule Of Accounts Payable And Accrued Liabilities (Detail)
Schedule Of Cash, Cash Equivalents And Available-For-Sale Securities By Significant Investment Category (Detail)
Schedule Of Cash, Cash Equivalents And Available-For-Sale Securities By Significant Investment Category (Parenthetical) (Detail)
Schedule Of Inventory (Detail)
Schedule Of Property Plant And Equipment Net (Detail)
Significant Accounting Policies
Significant Accounting Policies (Policies)
Stock Based Compensation - Additional Information (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Summary Of Changes In Accumulated Balances Of Aoci Including Current Period Other Comprehensive Income (Loss) And Reclassifications Out Of Aoci (Detail)
Summary Of Convertible Debt (Detail)
Summary Of Convertible Debt (Parenthetical) (Detail)
Summary Of Designated Forward Foreign Currency Exchange Contracts Outstanding (Detail)
Summary Of Interest Expense On Convertible Debt (Detail)
Summary Of Non-Designated Forward Foreign Currency Exchange Contracts Outstanding (Detail)
Summary Of Restricted Stock Unit Awards With Performance Conditions (Detail)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Supplemental Balance Sheet Information
Supplemental Balance Sheet Information (Tables)
Total Net Product Revenue Concentrations Attributed To Largest Customers (Detail)

Material Contracts, Statements, Certifications & more

Biomarin Pharmaceutical Inc provided additional information to their SEC Filing as exhibits

Ticker: BMRN
CIK: 1048477
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-18-025196
Submitted to the SEC: Thu Oct 25 2018 10:06:50 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Sunday, September 30, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bmrn/0001564590-18-025196.htm